Global Multiplexed
Diagnostic Market, by Product Type (Reagents & Consumables and
Instruments), by Application (Disease Diagnostics, Molecular Diagnostics, and
Drug Development), by End User (Hospitals, Clinical Laboratories, Academic
& Research Institutes, and Others), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa) is expected to be
valued at US$ 10,126.6 million in 2019 and is expected to exhibit a CAGR of
7.9% over the forecast period (2019-2027), as highlighted in a new report
published by Coherent Market Insights.
The increasing incidence of
chronic diseases such as cardiovascular disease (CVD), cancer, diabetes, and
respiratory diseases including asthma and chronic obstructive pulmonary disease
are expected to drive the multiplexed diagnostic market over the forecast
period. For instance, in 2016, the World Health Organization (WHO) estimated
around 40.5 million deaths due to non-communicable diseases (NCDs), which
include cardiovascular diseases, cancer, diabetes and chronic lung diseases.
The leading cause of deaths in 2016 was cardiovascular diseases, whereas 1.6
million people died due to diabetes.
Furthermore, according to the
Cancer Research UK, around 20 cases of ovarian cancers are diagnosed every day
and it is estimated to increase by around 15% from 2014 to 2035, while American
Cancer Society has estimated that in 2020, around 13,130 new cases of soft
tissue sarcomas will be diagnosed in the U.S.
Thus, increasing incidence of various cancer is expected to drive demand
for precise multiplexed diagnostic tools, which in turn is expected to fuel the
market growth.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/983
Browse 54 Market Data Tables and
35 Figures spread through 140 Pages and in-depth TOC on “Multiplexed Diagnostic
Market”- Global Forecast to 2027, by Product Type (Reagents & Consumables
and Instruments), by Application (Disease Diagnostics, Molecular Diagnostics,
and Drug Development), by End User (Hospitals, Clinical Laboratories, Academic
& Research Institutes, and Others), and by Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa).
Key players in the market are
focused on adoption of expansion strategies such as mergers and acquisitions,
collaborations, and partnerships, in order to expand their product portfolio
and global presence in the multiplexed diagnostic market. For instance, in
April 2019, Meridian Bioscience, Inc. entered into an agreement to acquire
GenePOC Inc., a Canada-based provider of molecular diagnostic instruments and
assays. With the acquisition Meridian Bioscience included state-of-the art
revogene molecular diagnostics platform of GenePOC Inc., in its diagnostics
portfolio. Through revogene, Meridian Bioscience offers gastrointestinal
disease and core respiratory illness diagnostics solutions to its customers.
Key Takeaways of the Global
Multiplexed Diagnostic Market:
The global multiplexed diagnostic
market is expected to exhibit a CAGR of 9% over the forecast period, owing to
rising incidence of chronic diseases and increasing product launches and
approvals. For instance, in October 2017, Mercodia AB launched the AKURIO Islet
Hormone multiplex assay with the collaboration of Quansys Bioscience.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/multiplexed-diagnostic-market-983
AKURIO is designed to assess four
different hormones in pancreatic study, which include glucagon, insulin,
C-peptide, and proinsulin. AKURIO Islet Hormone multiplex assay provides high
data accuracy with reliable speed.
Among product type, reagents
& consumables segment held a significant market share in 2018, owing to
increasing product launches and approvals. For instance, in January 2019,
Biocare Medical, LLC, launched VALENT IVD (in vitro diagnostic) automated
staining platform. VALENT is a fully automated, open platform, and merging
high-throughput user interface, which offers 48-slide capacity, multiplex
immunohistochemistry (IHC) capability, and high-quality staining.
Among application, disease
diagnostics segment held a significant market share in 2018, owing to
increasing product launches and approvals. For instance, in December 2019,
Co-Diagnostics, Inc. received approval from the Central Drug Standard Control
Organization (CDSCO), India, for Saragene. Saragene is designed to carry out
five diagnostic test which include Mycobacterium tuberculosis, malaria,
hepatitis B, hepatitis C, and human papillomavirus (HPV).
Companies operating in the global
multiplexed diagnostic market include Luminex Corporation, Thermo Fisher,
Illumine Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., Abbott Laboratories,
Siemens Healthineers, Agilent technologies, BioMerieux SA, and F.Hoffmann-La
Roche Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/983
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment